How Can Erythropoeitin-Stimulating Agent Use be Reduced in Chronic Dialysis Patients?

Adjuvant Therapies to Reduce Erythropoiesis-Stimulating Agent Dose Requirements

Authors

  • Hitesh H. Shah,

    1. Division of Kidney Diseases and Hypertension, Department of Medicine, North Shore University Hospital and Long Island Jewish Medical Center, Hofstra North Shore-LlJ School of Medicine, Great Neck, New York
    Search for more papers by this author
  • Steven N. Fishbane

    Corresponding author
    • Division of Kidney Diseases and Hypertension, Department of Medicine, North Shore University Hospital and Long Island Jewish Medical Center, Hofstra North Shore-LlJ School of Medicine, Great Neck, New York
    Search for more papers by this author

Address correspondence to: Steven Fishbane, MD, 100 Community Dr, 2nd Floor, Great Neck, NY 11021, Tel.: 516-465-8200, or e-mail: Sfishbane@NSHS.edu.

No abstract is available for this article.

Ancillary